| Literature DB >> 26990661 |
D R Green1, T H Oguin2, J Martinez2.
Abstract
Phagocytic cells of the immune system must constantly survey for, recognize, and efficiently clear the billions of cellular corpses that arise as a result of development, stress, infection, or normal homeostasis. This process, termed efferocytosis, is critical for the prevention of autoimmune and inflammatory disorders, and persistence of dead cells in tissue is characteristic of many human autoimmune diseases, notably systemic lupus erythematosus. The most notable characteristic of the efferocytosis of apoptotic cells is its 'immunologically silent' response. Although the mechanisms by which phagocytes facilitate engulfment of dead cells has been a well-studied area, the pathways that coordinate to process the ingested corpse and direct the subsequent immune response is an area of growing interest. The recently described pathway of LC3 (microtubule-associated protein 1A/1B-light chain 3)-associated phagocytosis (LAP) has shed some light on this issue. LAP is triggered when an extracellular particle, such as a dead cell, engages an extracellular receptor during phagocytosis, induces the translocation of autophagy machinery, and ultimately LC3 to the cargo-containing phagosome, termed the LAPosome. In this review, we will examine efferocytosis and the impact of LAP on efferocytosis, allowing us to reimagine the impact of the autophagy machinery on innate host defense mechanisms.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26990661 PMCID: PMC4987729 DOI: 10.1038/cdd.2015.172
Source DB: PubMed Journal: Cell Death Differ ISSN: 1350-9047 Impact factor: 15.828
Summary of the four major modes of cell death: apoptosis, necrosis, necroptosis and pyroptosis
| Active cellular death, largely controlled by a family of cysteine proteases called caspases
Apoptotic caspases are broadly grouped into initiator caspases (caspase-8 and -9) and executioner caspases (caspases-3, -6, and -7)
| Membrane ‘blebbing,' often with separation of apoptotic bodies DNA fragmentation Chromatin condensation Considered immunologically silent due to the packaging of possible danger-associated molecular patterns (DAMPs) into discreet, tolerogenic pieces Active phosphatidylserine (PtdSer) exposure (Annexin V positive) Propidium iodide or 7-AAD negative at early stages |
[ |
| | ||
| Characterized as an passive type of cell death that occurs independently of caspase activation Triggered in response to catastrophic damage or pathology, including infarction, mechanical trauma, ischemia, frostbite, and animal venom Apoptotic cells that are not efficiently cleared by phagocytes can undergo secondary necrosis independently of any apoptotic machinery | Cellular swelling (oncosis) Organelle swelling Nuclear distention Cellular rupture Releases inflammatory cellular contents (DAMPs) or alarmins that can activate neighboring immune cells via Toll-like receptor (TLR) signaling and other mechanisms Annexin V positive due to membrane rupture Propidium iodide or 7-AAD positive | [ |
| | ||
| Genetically programed cell death with the morphological features of necrosis Triggered by diverse forms of neurodegeneration, ischemia, or infection. Engagement of the extrinsic pathway (i.e., TNF–TNFR pathway) in the absence of caspase-8 can result in a necrotic cell death that requires the kinase activity of receptor interacting protein kinase1 (RIPK1) and RIPK3 RIPK3 phosphorylates and activates the pseudokinase, mixed lineage-kinase like (MLKL) Induces a conformational change that allows for its oligomerization and interaction with the plasma membrane through binding to phosphatidylinositol lipids to directly disrupt membrane integrity RIPK1 is required for a variety of innate immune signaling pathways, such as TLRs, interferons, and the RIG-I-MAVS pathway | Loss of plasma membrane integrity Swollen cellular organelles Releases inflammatory cellular contents (DAMPs) or alarmins that can activate neighboring immune cells via TLR signaling and other mechanisms Active PtdSer exposure (Annexin V positive) Propidium iodide or 7-AAD positive | [ |
| | ||
| Non-apoptotic, genetically programmed cellular death mediated by excessive inflammatory caspase activity (human caspase-1, -4, and -5; rodent caspase-1 and -11)
Required for cell death in a variety of experimental settings, including in the immune system, the cardiovascular system, and the central nervous system
Caspase-1 is activated by dimerization at complexes termed inflammasomes that form in the cytosol and detect a diverse repertoire of pathogenic molecules, including bacterial toxins and viral RNA
Activated caspase-1 in turn cleaves pro-IL-1 | Cellular rupture DNA fragmentation Releases inflammatory cellular contents (DAMPs) or alarmins that can activate neighboring immune cells via TLR signaling and other mechanisms Often Annexin V positive due to membrane rupture Propidium iodide or 7-AAD positive | [ |
Components of the efferocytosis machinery and their association with inflammatory and autoimmune diseases
| Nucleotides (ATP/UTP) | ‘Find-me' | MS/EAE | [ |
| Pannexin-1 | ‘Find-me' | MS/EAE, seizure disorders | [ |
| S1P | ‘Find-me' | MS/EAE | [ |
| LPC | ‘Find-me' | Atherosclerosis, SLE/systemic autoimmunity | [ |
| S1PR1-5 | ‘Find-me' | MS/EAE | [ |
| G2A | ‘Find-me' | SLE/systemic autoimmunity, atherosclerosis | [ |
| CX3CR | ‘Find-me' | Autoimmune uveitis, MS/EAE | [ |
| ICAM3 | ‘Eat-me' | RA, SLE/systemic autoimmunity, GBS, MS/EAE | [ |
| CRT | ‘Eat-me' | RA, Sjogren's syndrome, Celiac disease, SLE/systemic autoimmunity | [ |
| C1q | ‘Eat-me' | SLE/systemic autoimmunity, RA, atherosclerosis | [ |
| TIM1 | ‘Eat-me' | SLE/systemic autoimmunity, airway inflammation | [ |
| TIM3 | ‘Eat-me' | Airway inflammation, MS/EAE | [ |
| TIM4 | ‘Eat-me' | SLE/systemic autoimmunity | [ |
| BAI1 | ‘Eat-me' | Glioblastoma, neurological disorders | [ |
| Integrins (av | ‘Eat-me' | Scleroderma, ulcerative colitis | [ |
| MerTK | ‘Eat-me' | SLE/systemic autoimmunity, retinisis pigmentosa, atherosclerosis | [ |
| MFG-E8 | ‘Eat-me' | SLE/systemic autoimmunity, atherosclerosis | [ |
| ProteinS | ‘Eat-me' | Thrombosis, SLE/systemic autoimmunity | [ |
| CD300f | ‘Eat-me' | SLE/glomerulonephritis | [ |
| ELMO1 | Engulfment | Testicular pathology, impaired neurogenesis | [ |
| DOCK180 | Engulfment | Cardiovascular abnormalities, myogenesis abnormalities | [ |
| GRK6 | Engulfment | SLE/systemic autoimmunity | [ |
| RAC1 | Engulfment | RA, airway inflammation | [ |
| DNAse II | Processing | Polyarthritis | [ |
| LXR | Processing | MS/EAE, SLE/systemic autoimmunity, autoimmune uveitis, type I diabetes, atherosclerosis | [ |
| PPAR | Processing | MS/EAE, SLE/glomerulonephritis, atherosclerosis, osteoarthritis | [ |
| ABCA1 | Processing | SLE/glomerulonephritis | [ |
| Fractalkine (CX3CL1) | ‘Find-me' | Sjogren's syndrome, airway inflammation, RA | [ |
| Purigenic receptors (P2Y2) | ‘Find-me' | Sjogren's syndrome, autoimmune uveitis | [ |
| Integrins (av | ‘Eat-me' | MS/EAE | [ |
| CD91 (LRP) | ‘Eat-me' | RA, SLE/systemic autoimmunity | [ |
| RAGE | ‘Eat-me' | MS/EAE, DTH | [ |
| GAS6 | ‘Eat-me' | Thrombosis, nephrotoxic nephritis, SLE/systemic autoimmunity | [ |
Abbreviations: BA1, brain-specific angiogenesis inhibitor 1; DTH, delayed-type hypersensitivity; EAE, experimental autoimmune encephalitis; C1q, complement 1q; CRT, calreticulin; GBS, Guillain-Barré syndrome; LPC, lysophosphatidylcholine; LXR, liver X receptor; MFG-E8, milk fat globule-EGF factor 8; MS, multiple sclerosis; PPARδ/γ; peroxisome proliferator-activated receptor γ/δ; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; S1P, sphingosine-1-phosphate; TIM, T-cell immunoglobulin mucin receptor
Figure 1The recruitment of phagocytes and recognition of dying cells by phagocytes. (a) Dying cells release ‘find-me' signals, such as ATP, UTP, S1P, lysophosphatidylcholine (LPC), or fractalkine, that recruit phagocytes to sites of cell death. Phagocytes sense these ‘find-me' signals via cognate receptors (P2Y2, S1PRs, G2A, and CXCR3, respectively). (b) Phagocytes express a variety of receptors and bridging molecules that recognize and engage dying cells via ‘eat-me' signals exposed on apoptotic cell surfaces. The most common ‘eat-me' signal, phosphatidylserine (PtdSer or PS), engages the PtdSer-specific receptors, TIM1, TIM3, TIM4, BAI1, stabilin-2, and RAGE, as well as the PS-specific bridging molecules MFG-E8, Gas6, and protein S. These bridging molecules engage other surface engulfment receptors (αvβ3 or TAM) to facilitate uptake. Other ‘eat-me' signals, such as calreticulin (CRT) and ICAM3, exist and mediate recognition and engulfment via the receptors LRP (via C1q) and CD14, respectively
Components of the autophagic machinery and their association with inflammatory and autoimmune diseases
| NOX2 | LAP | CGD, Alzheimer's disease, Creuzfeldt–Jakob disease | [ |
| Rubicon | LAP | Ataxia | [ |
| Beclin1 | Autophagy LAP | Ovarian cancer, breast cancer, lung cancer, cystic fibrosis, Alzheimer's disease, RA | [ |
| VPS34 | Autophagy LAP | Schizophrenia | [ |
| UVRAG | Autophagy LAP | Stomach cancer, non-segmental vitiligo, colorectal cancer, cardiomyopthay | [ |
| ATG5 | Autophagy LAP | Airway inflammation, SLE/systemic autoimmunity, MS/EAE, RA, Alzheimer's disease, atherosclerosis | [ |
| ATG16L | Autophagy LAP | Crohn's disease, atheroclerosis | [ |
| ATG7 | Autophagy LAP | SLE/systemic autoimmunity, MS/EAE, type I diabetes, RA, Alzheimer's disease, cardiomyopathy | [ |
| ATG4 | Autophagy LAP | Otoconia | [ |
| LC3 | Autophagy LAP | Nasu-Hakola disease | [ |
| LAMP2 | Autophagy LAP | Danon disease, type II diabetes | [ |
| ULK1 | Autophagy | Crohn's disease | [ |
| FIP200 | Autophagy | Inflammatory skin disorders | [ |
| p62 | Autophagy | Huntingtin's disease | [ |
| EPG5 | Autophagy | Vici syndrome | [ |
| IRGM | Autophagy | Crohn's disease, MS/EAE | [ |
| SMURF1 | Autophagy | Ulcerative colitis | [ |
| WDR45 | Autophagy | Encephalopathy | [ |
| Parkin | Mitophagy | Parkinson's disease | [ |
| PINK1 | Mitophagy | Parkinson's disease | [ |
Abbreviations: ATG, autophagy-related gene; CGD, chronic granulomatous disease; EAE, experimental autoimmune encephalitis; LAP, LC3-associated phagocytosis; MS, Multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus
Confirmed activity in autophagy, LAP, and/or mitophagy is indicated
Figure 2The processing of engulfed dying cells requires LC3-associated phagocytosis (LAP) and promotes an anti-inflammatory response. Upon engulfment of dying cells, components of the LAP pathway are recruited to dead cell-containing phagosome (or LAPosome). The class III PI3 K complex, comprised of Beclin 1, VPS34, UVRAG, and Rubicon, is critical to the sustained and localized production of PI(3)P at the LAPosome. PI(3)P serves two roles – the recruitment of the downstream LAP machinery (such as ATG5, ATG12, ATG16L, and ATG7) and stabilization of the NOX2 complex for the production of ROS. Rubicon is also required for the stabilization of the NOX2 complex. Both ROS and PI(3)P are required for successful LC3-II decoration of the LAPosome, and LC3-II is required for fusion to the lysosome and maturation of LAPosome. The anti-inflammatory effects of efferocytosis are mediated by the activity of lipid and cholesterol sensors, such as ABCA1, LXR, PPARγ/δ, and PGC-1β, leading to the production of IL-10 and TGFβ, whereas pro-inflammatory mediators, such as IL-12, are actively repressed